Respiratory Cachexia Nutrition Market

How big is Respiratory Cachexia Nutrition Market in 2026?

USD 161.9 million in 2026 and USD 362.8 million by 2036 at an 8.4% CAGR.

Demand for respiratory cachexia nutrition is projected to rise from USD 161.9 million in 2026 to USD 362.8 million by 2036 at 8.4% CAGR. Respiratory teams generate repeat use after identifying low BMI or involuntary weight loss that ordinary meals cannot correct within tolerated intake. A 2025 European Respiratory Society Congress study of 62 men with COPD found malnutrition concentrated in ABE group E. The concentration makes nutrition screening relevant during severe COPD follow-up, where intervention can start before further weight loss reduces intake capacity.

Commercial conversion depends on patients entering diagnosed care early enough to receive nutrition assessment and continue treatment at home. KDCA updated COPD guidance in June 2026 and estimated prevalence near 13% among South Korean adults aged 40 or older. The guidance reported diagnosis at 2.8% and treatment at 1.6% of patients with COPD. The treatment gap narrows the patient pool entering sustained medical nutrition despite substantial underlying disease burden.

Key Takeaways

• Respiratory nutrition demand grows as clinicians identify low BMI and muscle loss early enough to prescribe sustained nutritional support.
• By formulation, energy-dense low-volume ONS is estimated to hold 49.5% in 2026 owing to concentrated servings that reduce daily intake volume.
• Advanced COPD is projected to account for 47.1% of condition demand in 2026 because weight loss is clinically visible within repeated respiratory care.
• RTD is expected to represent 42.7% of product-form demand in 2026 as pre-measured servings remove preparation steps during daily use.
• Poor adherence and uneven coverage can interrupt repeat oral nutrition use before patients complete the intended nutrition plan.
• Some of the key players in this market include Abbott Laboratories (PULMOCARE / Ensure), Nestlé Health Science, Nutricia (Danone), Fresenius Kabi, Meiji Co., Ltd. (Meiji Holdings), Medtrition, Inc., Megalabs USA, LLC, and B. Braun SE.

Analyst Perspective

"Respiratory cachexia nutrition should be evaluated by the amount a patient can consume each day, not by nutrient density alone. Commercial value follows once clinicians can start an appropriate formula and patients can obtain the same product consistently following discharge."

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights

How is the respiratory cachexia nutrition market segmented?

The respiratory cachexia nutrition market is segmented by formulation, condition, product form, end user and sales channel.

Formulation covers energy-dense low-volume ONS, omega-3 - EPA-enriched blends, leucine - HMB anti-catabolic products and other formulations. Condition includes advanced COPD, ILD and pulmonary fibrosis, bronchiectasis and other respiratory conditions associated with nutrition risk. Product form separates RTD and powders from puddings, semi-solids and other formats used during supplementation. End users include homecare, hospitals and long-term care while sales channels cover hospital pharmacy, retail pharmacy, online and institutional tender routes.

Why does advanced COPD lead the condition category?

Advanced COPD gives respiratory teams a defined reason to monitor nutritional decline because breathlessness and exacerbations can reduce intake. GOLD 2026 instructs clinicians to measure BMI at every visit and maintain adequate nutrition during COPD management. Routine BMI checks give clinical nutrition a clearer entry point than respiratory conditions with inconsistent nutrition screening.

• Advanced COPD is projected to account for 47.1% of condition demand in 2026 attributable to visible weight loss and routine nutrition assessment.
• Clinicians can link supplementation to weight history and intake records instead of treating nutrition loss outside respiratory management.

Why does energy-dense low-volume ONS lead the formulation category?

Breathlessness and early satiety can make standard oral clinical nutrition supplements volumes unrealistic during repeated treatment. Fresenius stated in its 2025 annual report that it added Fresubin PROTEIN Shot for increased protein needs and low-volume tolerance. Smaller servings let dietitians raise calorie or protein delivery without displacing ordinary meals during treatment.

• By formulation, energy-dense low-volume ONS is estimated to hold 49.5% in 2026 owing to concentrated servings that reduce daily intake volume.
• Repeated use depends on patients finishing the prescribed volume during poor appetite or breathlessness without displacing meals.

Why does RTD lead the product form category?

RTD formats remove mixing and measurement from routines that may already include inhalers and daily therapies. Meiji announced in March 2025 that its Meibalance Mini Cup soup series would provide 200 kcal in a 125 mL serving and add onion soup flavor. Ready-to-use therapeutic nutrition becomes relevant if preparation burden reduces routine intake outside supervised care.

• RTD is expected to represent 42.7% of product-form demand in 2026 driven by immediate use and consistent serving volume.
• Flavor variety can extend repeat consumption since patients do not need preparation before each nutrition occasion.

Why does homecare lead the end user category?

Homecare determines whether a hospital nutrition recommendation becomes a routine purchase once patients resume daily therapies. NHS Hampshire and Isle of Wight stated in March 2026 that adult community ONS should provide an additional 600 to 1,000 kcal per day. The stated calorie target makes home healthcare continuity important because missed access immediately cuts prescribed intake.

• By end user, homecare is estimated to capture 49.8% in 2026 supported by oral consumption continuing after discharge.
• Storage convenience and local supply determine whether patients maintain the planned dose between respiratory follow-up visits.

Why does hospital pharmacy lead the sales channel category?

Hospital pharmacies influence first product selection during exacerbation admissions because dietitians can assess weight loss before discharge. OHID recorded 118,975 emergency COPD admissions in England during the financial year ending 2025. Adjacent enteral nutrition pathways explain why institutional stock can determine which product patients first receive.

• Hospital pharmacy is forecast to account for 47.3% of sales-channel demand in 2026 owing to formulary selection during inpatient care.
• A formulary decision has greater value if discharge instructions preserve product continuity through hospitalization and community transition.

What are the drivers, restraints and opportunities in the Respiratory Cachexia Nutrition Market?

Earlier recognition of disease-related malnutrition supports use, while adherence and payment gaps limit continuity and compact protein-focused formats improve daily tolerance.

• Driver: Respiratory teams are treating weight loss and low BMI as clinical findings that require a defined nutrition response.
• Restraint: Flavor fatigue and inconsistent access can stop oral supplementation before the intended calorie or protein target is sustained.
• Opportunity: Compact high-protein products can reduce serving burden and give clinicians more practical options for repeated home use.

Clinical recognition turns nutritional loss into a treatment trigger

Disease-related malnutrition becomes commercially relevant once clinicians identify it early enough to prescribe a repeatable intervention. BAPEN published a November 2025 position statement calling for early detection and evidence-based nutritional care for people at risk of disease-related malnutrition. Early detection gives medical food a defined role once respiratory teams link weight loss to a documented nutrition plan instead of general dietary advice.

Adherence can break the repeat-use cycle

A prescribed ONS loses repeat use if taste fatigue or routine burden causes patients to stop taking it. Nutricia reported in September 2025 that flavor monotony contributed to non-adherence among 48% of patients using oral nutritional supplements. The 48% finding makes flavor choice a continuity issue for patients already managing respiratory therapies and meal changes. oral clinical nutrition desserts show one adjacent format route for reducing repetition without changing the clinical nutrition objective.

Compact protein delivery fits low-volume use

Manufacturers can improve repeat use by concentrating protein into smaller servings that fit existing eating and medication routines. Medtrition launched ProSource Cup and ProSource Cup Plant in March 2025 with 20 grams of protein in a low-volume cup for oral or tube-fed patients. The 20-gram serving gives a protein supplement route for respiratory care where calorie density alone does not address muscle loss or low-volume tolerance.

Which country CAGRs are profiled in the Respiratory Cachexia Nutrition Market?

Country	CAGR
South Korea	8.9%
USA	8.0%
UK	7.7%
Germany	7.2%
Japan	6.3%

How do country-level CAGRs compare in the Respiratory Cachexia Nutrition Market?

Country forecasts span 2.6 percentage points between South Korea at 8.9% and Japan at 6.3%. South Korea and the USA form the upper pair while the UK and Germany follow closely. Japan defines the lower boundary because diagnosis depth and funded continuity explain differences better than rank.

• South Korea retains untreated COPD cases that leave nutrition need outside regular respiratory follow-up.
• The USA offers retail availability while oral products sit outside Medicare enteral nutrition benefits.
• The UK carries dietitian recommendations into community care through respiratory review and discharge pathways.
• German pharmacies support clinician-directed nutrition and reduce reliance on direct consumer product discovery channels.
• Japan favors familiar small-cup nutrition formats that lower switching friction for established domestic brands.

Comparable CAGRs produce different revenue conditions, and the full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Country-wise Analysis

• Hospital and retail channels in the USA let clinicians start oral nutrition through several routes, but payment differs by benefit design. Respiratory cachexia nutrition demand in the USA is forecast to rise at 8.0% CAGR over the forecast period owing to diagnosed COPD volume. NCHS reported in May 2025 that COPD affected 3.8% of adults in 2023 and 10.5% of adults aged 75 or older. Older patients create more nutrition-review opportunities while fragmented reimbursement can interrupt continuity after an oral product is recommended. Manufacturers need payer-specific evidence and geriatric care services channels that preserve access after hospital or outpatient initiation.
• COPD prevalence varies materially among English local authorities and changes the number of patients reaching nutrition review in each service area. The Chief Medical Officer documented a roughly 0.5% to 3.8% local-authority prevalence range in September 2025 using 2024 data. The UK respiratory cachexia nutrition outlook is anticipated to advance at 7.7% CAGR over the assessment period supported by routine respiratory review structures. Local formularies can narrow product access even where dietitians identify the same clinical need. Manufacturers with clear formulary evidence and reliable discharge supply can preserve repeat use without forcing patients to switch products after acute care.
• Statutory insurance in Germany can fund balanced enteral diets if ordinary food and other measures cannot adequately correct nutritional intake. Adoption of respiratory cachexia nutrition in Germany is estimated to expand at 7.2% CAGR through 2036 attributable to a defined prescription route. The G-BA approved an evaluation concept in June 2025 covering current provision of balanced enteral diets and rules that may need adjustment. Medical necessity gives clinicians a funded route while documentation requires proof that ordinary nutrition measures are insufficient. Manufacturers need evidence packages that fit German prescription criteria without making disease claims beyond the supported product indication.
• Small portions and palatability carry unusual weight in Japan because older patients may need concentrated nutrition without increasing meal volume. Japan’s Statistics Bureau reported in September 2025 that 36.19 million people were aged 65 or older and represented 29.4% of the population. Respiratory cachexia nutrition sales in Japan are forecast to expand at 6.3% CAGR by 2036 driven by an aging patient base and familiar medical nutrition formats. Taste and texture preferences can weaken repeat use even where nutrition need is clear. therapeutic food delivery gives manufacturers another route to test convenient formats without increasing the serving size patients must tolerate.
• COPD care in South Korea often involves several chronic conditions that compete for attention during the same follow-up visit. KDCA reported in July 2026 that 94.5% of patients with COPD had at least one comorbidity in national research. Multimorbidity gives clinicians a direct reason to review weight and nutritional status during ongoing respiratory care. South Korea is estimated to post 8.9% CAGR over the forecast period driven by a sizable clinical burden and wider chronic-disease management. Nutrition can still be delayed if urgent medical priorities dominate limited clinical consultation time. Simple home formats and respiratory-clinic education can keep nutrition visible without presenting the product as general wellness support.

Who are the notable companies in the Respiratory Cachexia Nutrition Market?

Abbott Laboratories (PULMOCARE / Ensure), Nestlé Health Science, Nutricia (Danone), Fresenius Kabi, Meiji Co., Ltd. (Meiji Holdings), Medtrition, Inc., Megalabs USA, LLC, and B. Braun SE are notable companies serving the defined market.

Clinical nutrition groups and specialty supplement companies compete on serving volume and nutrient density. Hospital access and home availability determine whether a selected product stays obtainable following discharge. Broad portfolios compete beside narrower protein and specialty offers without forming one universal product hierarchy.

• Abbott Laboratories and Nestlé Health Science serve broad adult medical nutrition routes alongside Nutricia (Danone) in hospital and community care.
• Fresenius Kabi and B. Braun SE participate through institutional nutrition routes alongside Meiji Co., Ltd. in concentrated medical nutrition formats.
• Medtrition, Inc. focuses on modular protein while Megalabs USA, LLC serves specialty nutrition routes used beside complete oral formulas.

Competitive Benchmarking: Respiratory Cachexia Nutrition Market

Company	Medical Nutrition Breadth	Compact Oral Nutrition Activity	Care-Channel Reach	Geographic Reach
Abbott Laboratories (PULMOCARE / Ensure)	High	High	High	Global
Nestlé Health Science	High	Medium	High	Global
Nutricia (Danone)	High	High	High	Global
Fresenius Kabi	High	High	High	Global
Meiji Co., Ltd. (Meiji Holdings)	Medium	High	Medium	Japan and selected international markets
Medtrition, Inc.	Medium	High	High	North America with international distribution
Megalabs USA, LLC	Medium	Medium	Medium	Americas with selected export markets
B. Braun SE	High	Medium	High	Global

Scoring basis: High medical nutrition breadth requires several documented clinical nutrition routes spanning complete and specialized nutrition products. Medium marks a narrower disease or supplement focus, and Low identifies one documented nutrition route. High compact oral nutrition activity requires documented high-energy or high-protein formats sold for repeated oral use. Medium represents narrower current oral activity, and Low identifies one documented compact oral role. High care-channel reach requires documented hospital access plus at least one community or retail route. Medium indicates one narrower institutional or community footprint, and Low marks a single documented access route. Ratings use documented capability only, and missing evidence never converts automatically into a Low score.

Key Developments in the Respiratory Cachexia Nutrition Market

• In July 2025, Danone completed its majority acquisition of Kate Farms and expanded specialized nutrition access through hospital plus home and retail channels.
• In October 2025, Nestlé Health Science entered a research partnership with UC Davis to advance nutrition programs covering healthy aging and disease-specific care.
• In September 2026, Meiji announced the Meibalance Mini Cup HighPro series for a September 14 launch with 200 kcal in each 125 mL serving.

Key Players in the Respiratory Cachexia Nutrition Market

Broad adult medical nutrition platforms

• Abbott Laboratories (PULMOCARE / Ensure)
• Nestlé Health Science
• Nutricia (Danone)
• Fresenius Kabi

Compact medical nutrition and institutional care

• Meiji Co., Ltd. (Meiji Holdings)
• B. Braun SE

Modular and specialty nutrition providers

• Medtrition, Inc.
• Megalabs USA, LLC

Respiratory Cachexia Nutrition Market - Report Scope

Coverage field	Report scope
Market breakdown	By formulation, condition, product form, end user, sales channel and region.
Quantitative Units	USD million.
Market Definition	Revenue from medical nutrition products purchased to support respiratory disease-related cachexia or malnutrition within the stated formulations, conditions, product forms, end users and sales channels. Ordinary foods, sports nutrition, parenteral nutrition and feeding devices are excluded.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, South Korea, and more than twenty-five additional countries included in the full report.
Key Companies	Abbott Laboratories (PULMOCARE / Ensure), Nestlé Health Science, Nutricia (Danone), Fresenius Kabi, Meiji Co., Ltd. (Meiji Holdings), Medtrition, Inc., Megalabs USA, LLC, B. Braun SE.
Forecast Period	2026 to 2036.
Approach	Primary and secondary research with market triangulation.

Respiratory Cachexia Nutrition Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Respiratory Cachexia Nutrition Market by Segments

Respiratory Cachexia Nutrition Market segmented by Formulation:

• Energy-Dense Low-Volume ONS
• Omega-3 - EPA-Enriched Blends
• Leucine - HMB Anti-Catabolic Products
• Others

Respiratory Cachexia Nutrition Market segmented by Condition:

• Advanced COPD (Pink Puffer Phenotype)
• ILD & Pulmonary Fibrosis
• Bronchiectasis
• Others

Respiratory Cachexia Nutrition Market segmented by Product Form:

• RTD
• Powders
• Puddings & Semi-Solids
• Others

Respiratory Cachexia Nutrition Market segmented by End User:

• Homecare
• Hospitals
• Long-Term Care
• Others

Respiratory Cachexia Nutrition Market segmented by Sales Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Institutional Tender
• Others

Respiratory Cachexia Nutrition Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• European Respiratory Society. (2025). COPD and malnutrition: ABE classification identifies risk better than GOLD. European Respiratory Journal, 66(Suppl. 69), PA2525.
• British Association for Parenteral and Enteral Nutrition. (2025, November 13). BAPEN publishes new position statement on “Malnutrition: Balancing Disease-Related and Psychosocial Aspects of Nutritional Care”.
• Global Initiative for Chronic Obstructive Lung Disease. (2026). 2026 GOLD report and pocket guide.
• Fresenius SE & Co. KGaA. (2026). Fresenius annual report 2025: Research and development.
• Meiji Co., Ltd. (2025, March 11). Meibalance Mini Cup soup taste series launch.
• NHS Hampshire and Isle of Wight. (2026, March 31). Prescribing oral nutritional supplements for adults in the community.
• Office for Health Improvement and Disparities. (2026, May 6). Respiratory disease profile: Statistical commentary, May 2026.
• Danone. (2025, September 22). Fortimel PlantBased Protein: Innovation with a savory oral nutritional supplement for malnutrition.
• Medtrition, Inc. (2025, March 25). Medtrition, Inc. launches the ProSource Cup portfolio.
• National Center for Health Statistics. (2025, May). Chronic obstructive pulmonary disease in adults age 18 and older: United States, 2023. NCHS Data Brief No. 529.
• Department of Health and Social Care. (2025, September 25). Health trends and variation in England, 2025.
• Gemeinsamer Bundesausschuss. (2025, June 18). Konzept zur Evaluation der Entwicklung der Leistungen zur Versorgung der Versicherten mit bilanzierten Diäten zur enteralen Ernährung.
• Statistics Bureau of Japan. (2025, September 14). Statistical topics No. 146: Elderly people in Japan.
• Korea Disease Control and Prevention Agency. (2026, June 1). Chronic obstructive pulmonary disease.
• Korea Disease Control and Prevention Agency. (2026, July 9). COPD patients face greater severe exacerbation burden when cardiovascular disease is present.
• Danone. (2025, July 1). Danone completes the acquisition of Kate Farms, enhancing its USA specialized nutrition offerings.
• Meiji Co., Ltd. (2026, September 7). Meibalance Mini Cup HighPro series announced for September 14 launch.
• Abbott. (2025, November 13). Abbott launches new and advanced Ensure Diabetes Care.
• Abbott. (2026, May 13). Abbott launches Ensure Strength Pro in India to support healthy ageing.
• Nestlé Health Science. (2026, March 30). Nestlé introduces an innovative complete nutritional solution for children with special medical nutrition needs.
• Nestlé Health Science. (2025, October 15). Nestlé Health Science and University of California, Davis Innovation Institute for Food & Health announce partnership to accelerate innovation in nutrition and health science.
• Fresenius Kabi. (2026, March 18). Innovating in plant-based nutrition.
• Fresenius Kabi. (2025, September 1). MOTIV launches new content for the nutritional management of chronic obstructive pulmonary disease.
• Imprenta Nacional de Costa Rica. (2025, August 11). Registro de cambio de nombre de Victus Inc por Megalabs USA LLC.
• Fresenius Kabi. (2025, June 26). New R&D center in India strengthens Fresenius Kabi’s innovation network.
• Nestlé Health Science. (2025, October 17). Nestlé Health Science and the Food & Nutrition Innovation Institute at the Friedman School at Tufts University expand opportunities to advance nutrition science and innovation.
• Nestlé Health Science. (2025, November 3). Nestlé Health Science to collaborate with universities in the USA and Australia to further the science of nutrition.
• Danone Nutricia. (2025, February 25). Nutricia lanza Fortimel Plantbased Protein®, un nuevo suplemento nutricional oral hiperproteico completamente vegetal para el manejo de la DRE.
• Meiji Co., Ltd. (2026, September 7). Meibalance Soft Jelly apple-yogurt and mixed-fruit-yogurt flavors announced for September 14 launch.
• USA Department of Veterans Affairs, National Acquisition Center. (2025, September 8). Contract 36W79725D0005: Medtrition, Inc.
• Canadian Intellectual Property Office. (2025, November 28). B|BRAUN - 2440451.
• B. Braun SE. (2026). Annual report 2025

This Report Answers

• How large is the respiratory cachexia nutrition market in 2026 and 2036?
• Which clinical conditions turn respiratory weight loss into sustained medical nutrition use?
• Why does energy-dense low-volume ONS account for 49.5% of formulation demand in 2026?
• Why does advanced COPD account for 47.1% of condition demand in 2026?
• Why does RTD represent 42.7% of product-form demand in 2026?
• How do growth rates differ among the USA, UK, Germany, Japan and South Korea?
• Which companies participate in adult medical nutrition and specialty supplement routes?
• Which adherence and payment conditions can interrupt repeat oral nutrition use?